Doxycycline 50Mg Tablet
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Toxicity
Conditions
Skin Toxicity
Trial Timeline
May 10, 2018 → Apr 6, 2020
NCT ID
NCT03448731About Doxycycline 50Mg Tablet
Doxycycline 50Mg Tablet is a phase 2 stage product being developed by Amgen for Skin Toxicity. The current trial status is completed. This product is registered under clinical trial identifier NCT03448731. Target conditions include Skin Toxicity.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03448731 | Phase 2 | Completed |
Competing Products
20 competing products in Skin Toxicity